Iovance Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Iovance Biotherapeutics (IOVA).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

1S.Buy

8Buy

4Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$12Upside to Avg. PT-15.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$15→$18
Oct 8, 2026	Baird	Colleen Kusy	PT Raise	Neutral	$6→$11
Sep 30, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$14→$18
Sep 29, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$9→$20
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$15
Sep 17, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$13→$15
Aug 25, 2026	TD Cowen	Nicholas Lorusso	PT Raise	Buy	$7→$10
Aug 20, 2026	UBS	David Dai	PT Raise	Neutral	$4→$7
Aug 18, 2026	Mizuho	Mara Goldstein	PT Raise	Outperform	$10→$11
Aug 7, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$11→$13
Aug 7, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$5→$8
May 7, 2026	Chardan Capital	Geulah Livshits	PT Cut	Buy	$16→$14
Apr 10, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$16
Mar 5, 2026	UBS	David Dai	PT Raise	Neutral	$2→$4
Mar 3, 2026	Citizens	Reni J. Benjamin	Upgrade	Market Perform→Market Outperform	$5
Feb 25, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$10→$11
Feb 25, 2026	Citizens	Reni J. Benjamin	Upgrade	Market Perform→Market Outperform	$5
Dec 17, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$9→$10
Nov 24, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$4→$9
Nov 6, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$20→$17

Analyst Ratings News

PRO
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.

Benzinga Newsdesk

PRO
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.

Benzinga Newsdesk

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

PRO
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

PRO
Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

PRO
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

PRO
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

PRO
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

People Also Watch

People Also Watch

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

PROBaird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

PROWells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

PROHC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

PROGoldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

PROBarclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

PRO
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

PRO
Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

PRO
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

PRO
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

PRO
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15